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The specific impact of mutations that abrogate human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) dimerization on virus replication is not known, as mutations shown previously to inhibit RT
dimerization also impact Gag-Pol stability, resulting in pleiotropic effects on HIV-1 replication. We have
previously characterized mutations at codon 401 in the HIV-1 RT tryptophan repeat motif that abrogate RT
dimerization in vitro, leading to a loss in polymerase activity. The introduction of the RT dimerization-
inhibiting mutations W401L and W401A into HIV-1 resulted in the formation of noninfectious viruses with
reduced levels of both virion-associated and intracellular RT activity compared to the wild-type virus and the
W401F mutant, which does not inhibit RT dimerization in vitro. Steady-state levels of the p66 and p51 RT
subunits in viral lysates of the W401L and W401A mutants were reduced, but no significant decrease in
Gag-Pol was observed compared to the wild type. In contrast, there was a decrease in processing of p66 to p51
in cell lysates for the dimerization-defective mutants compared to the wild type. The treatment of transfected
cells with indinavir suggested that the HIV-1 protease contributed to the degradation of virion-associated RT
subunits. These data demonstrate that mutations near the RT dimer interface that abrogate RT dimerization
in vitro result in the production of replication-impaired viruses without detectable effects on Gag-Pol stability
or virion incorporation. The inhibition of RT activity is most likely due to a defect in RT maturation, suggesting
that RT dimerization represents a valid drug target for chemotherapeutic intervention.
The human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) is critical for HIV-1 replication and is re-
quired for the conversion of the genomic viral RNA into a
double-stranded proviral DNA precursor, catalyzed by the
RNA- and DNA-dependent polymerase and RNase H activi-
ties of the enzyme. The biologically relevant form of HIV-1 RT
is a heterodimer composed of 66 (p66)- and 51-kDa (p51)
polypeptides. The p51 subunit is derived from and is identical
to the N-terminal polymerase domain of p66 (9). The p66
subunit can be divided structurally into the polymerase and
RNase H domains, with the polymerase domain further di-
vided into the fingers, palm, thumb, and connection subdo-
mains (24, 29). One functional polymerase and RNase H active
site is located on the p66 subunit, which adopts an “open”
structure to accommodate the nucleic acid template/primer
(24, 29). The p51 subunit has the same polymerase subdomains
as p66. However, the spatial orientations of the individual
subdomains differ from those in p66, with the p51 subunit
assuming a “closed” structure and playing a largely structural
role in the heterodimer (2, 23, 32). Structural analyses reveal
three major contacts between the p66 and p51 subunits, which
include interactions between the connection subdomains of
both subunits, with most of the interaction surface being
largely hydrophobic (4, 59).
The appropriate association of the p66 and p51 RT subunits
is required for activation of the enzyme, as monomeric sub-
units are devoid of polymerase activity (41, 51, 53). In vitro
dimerization of the p66 and p51 subunits can be achieved
under nonphysiological conditions and appears to occur by a
two-step process involving the initial formation of an interme-
diate that can bind the template/primer but lacks polymerase
activity followed by conformational changes resulting in an
active enzyme (11). While this in vitro study may not exactly
represent how RT maturation occurs in infected cells, it does
demonstrate the absolute requirement for RT dimerization to
activate polymerase function, making RT dimerization an at-
tractive drug target (21, 48, 51, 53). Despite several in vitro
studies demonstrating the critical role of RT dimerization in
enzyme activation (51, 53), the specific impact of abrogating
RT dimerization on HIV-1 replication has not been deter-
mined.
The HIV-1 RT is expressed as part of a Gag-Pol polyprotein
(Pr160gag-pol), which consists of the structural proteins matrix
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(MA), capsid (CA), p2, and nucleocapsid (NC) and the Pol-
encoded functional enzymes protease (PR), RT, and integrase
(IN) (20). A transframe region links the Gag and the Pol
domains and consists of an N-terminal octapeptide and p6pol
that are separated by an HIV-1 protease cleavage site (15).
Pr160gag-pol is translated from a full-length viral RNA once
every 20 Gag (Pr55gag) translation events by a ribosomal
frameshift mechanism (66). Proteolytic processing by the pol-
encoded PR results in the sequential cleavage of Gag and
Gag-Pol during or shortly after viral particle release (27), re-
sulting in the formation of mature structural proteins and viral
enzymes (58). The precise pathway for the formation of RT
heterodimers in HIV-1-infected cells is not established, al-
though it is proposed to occur through a p66/p66 homodimer
intermediate (59). Recent data based on a model 90-kDa Pol
polyprotein (which consists of the transframe region, PR, RT,
and the N terminus of IN) support this model (45). The study
of mutations that abrogate RT dimerization is likely to shed
light on the intermediates involved in the formation of stable
RT heterodimers in HIV-1-infected cells.
The RT tryptophan repeat motif represents a remarkable
cluster of six tryptophan residues, at codons 398, 401, 402, 406,
410, and 414, five of which are separated by three amino acid
residues (3). The tryptophan repeat motif is found in the con-
nection subdomain of both HIV-1 RT subunits. This hydro-
phobic cluster is highly conserved among primate lentiviral
reverse transcriptases (3), although it is not found in other
lentiviral RTs known to form heterodimers, including feline
immunodeficiency virus RT. The tryptophan repeat motif is
also absent from RTs from other retrovirus families, including
those of the heterodimeric avian sarcoma leukosis virus and
Moloney murine leukemia virus, which may dimerize when
presented with a template (56). Previous studies suggested that
the tryptophan repeat motif is important for RT heterodimer-
ization, as the elucidation of the kinetics of the association of
p66 and p51 RT subunits in vitro implicates the RT tryptophan
residues as being involved in the initial interaction of the two
monomers (10). These data are supported by our studies,
which demonstrate that mutations of the highly conserved
tryptophans at codons 401 and 414 in the context of the p66
subunit abrogate RT heterodimerization, as observed in both a
yeast two-hybrid system for RT dimerization and in vitro bind-
ing assays (51).
The study and interpretation of the impact of mutations in
RT and IN on HIV-1 replication are usually complicated by
their effects on the stability and function of the Gag-Pol
polyprotein from which RT and IN are expressed (34, 44, 65).
A trans-complementation system has been developed to study
the impact of mutations in specific subunits of the HIV-1 RT,
where RT and IN are delivered into viral particles in trans
fused to HIV-1 Vpr (35, 64). While this system is useful for
examining the effect of RT mutations on intracellular reverse
transcription, it is unlikely to recapitulate the maturation of the
HIV-1 RT heterodimer from the Gag-Pol polyprotein as it
occurs in HIV-1-infected cells. Hence, to examine the impact
of RT dimerization-blocking mutations on RT maturation and
function, it is necessary to perform these experiments in the
context of the full-length virus, using mutations that are not
expected to impact Gag-Pol stability or its packaging into the
virion.
Examples of RT mutations at primer grip residues L234 and
W229 that abrogate RT dimerization have been described (6,
14, 26, 52, 62). The primer grip region of HIV-1 RT is impor-
tant for maintaining the primer terminus in an orientation
appropriate for nucleophilic attack by the incoming de-
oxynucleoside triphosphate (37) and is not near the RT dimer
interface (24, 29). Previous studies which examined the impact
of mutations in or near the RT primer grip region on HIV-1
replication demonstrated decreased viral infectivity due to de-
fects in Gag-Pol stability (65). The L234D primer grip mutant
produced HIV-1 with a reduced infectivity as a result of defects
in virion maturation that were ascribed to the premature cleav-
age of Pr160gag-pol in the cell, leading to a reduction in the
virion incorporation of pol gene products (65). Since the
primer grip region is far from the dimer interface, mutations at
L234 that negate RT dimerization are likely to do so through
long-range conformational changes that may also impact the
conformation and stability of Pr160gag-pol. In contrast, W401 is
close to the RT dimer interface, and mutation of this residue to
either an alanine or leucine in the context of p66 abrogates the
interaction with p51 in vitro (51). Our studies demonstrate that
the effect of mutating W401 is mainly localized to the reposi-
tioning of a loop region between amino acids W401 and W414
in the p66 subunit (51). Furthermore, a circular dichroism
analysis of recombinant RT heterodimers expressing either the
W401A or W401L mutation demonstrated no significant
change in secondary structure or misfolding of the protein
compared to wild-type RT (53). Since RT W401 is near the
dimer interface, we hypothesized that the impact of mutations
at this residue on the stability and structure of Pr160gag-pol
would be minimal, enabling us to probe the specific effect of
mutations that abrogate RT dimerization on RT maturation in
the context of a full-length infectious virus.
In this study, we show that RT dimer interface mutations at
amino acid W401 result in the production of viral particles with
dramatically reduced infectivities and specific defects in RT
maturation and function. Notably, this phenotype was ob-
served in the absence of detectable Gag-Pol instability and
virion packaging defects. Furthermore, our data provide evi-
dence in support of the ideas that the immediate precursor of
the RT heterodimer is the p66 homodimer and that the abro-
gation of RT dimerization represents a valid drug target for
chemotherapeutic intervention.
MATERIALS AND METHODS
Cell culture. The 293T and TZM-bl (60) cell lines were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum
(Progen, Darra, Queensland), glutamine (292 g/ml), penicillin (100 U/ml), and
streptomycin (100 g/ml) (DMEM-10). TZM-bl cells were obtained through the
NIH AIDS Research and Reference Reagent Program, Division of AIDS, Na-
tional Institute for Allergy and Infectious Diseases (NIAID), National Institutes
of Health (NIH), and were contributed by John C. Kappes, Xiaoyun Wu, and
Tanzyme Inc. MT-2 cells (16) were maintained in RPMI 1640 supplemented with
10% fetal calf serum, glutamine (29.2 g/ml), penicillin (100 U/ml), and strep-
tomycin (100 g/ml).
Antibodies. The monoclonal antibodies 11G10 and 5B2 recognize HIV-1 RT
epitope 1 (codons 193 to 284) and HIV-1 RT epitope 2 (codons 294 to 319),
respectively, and were generously provided by Dag Helland (University of Ber-
gen, Norway) (50). The monoclonal antibody 8E5 recognizes the C-terminal
epitope (codons 262 to 271) of HIV-1 IN (36) and was provided by Dag Helland.
A p24 monoclonal antibody to the HIV-1 capsid (p24), purified by Andy Poum-
bourios (St. Vincent’s Institute of Medical Research, Melbourne, Australia)
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from an HIV-1 p24 hybridoma (183-H12-5C), was obtained through the NIH
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH, and was contributed by Bruce Chesebro (7). Pooled sera from HIV-
infected patients were also used to detect HIV-1 gag and pol gene products (22).
Drug. Indinavir sulfate was prepared as a 10 mM stock in sterile water and was
obtained through the NIH AIDS Research and Reference Reagent Program.
HIV-1 proviral clones and site-directed mutagenesis. The plasmid pSVC21
contains the infectious HXB2 molecular clone of HIV-1 (12). Mutations at RT
amino acid W401 were introduced by site-directed mutagenesis using a Gene-
Editor mutagenesis kit (Promega, Madison, Wis.) into the clone pBPol contain-
ing the Apa1-SalI fragment of HXB2 (nucleotides 2006 to 5786) cloned into the
ApaI-SalI sites of pBluescript II SK() (Stratagene, La Jolla, CA). The muta-
genic oligonucleotides 5-GGAAACATGGGAAACCGCGTGGACAGAGTA
TTGG-3, 5-GGAAACATGGGAAACGTTGTGGACAGAGTATTGG-3,
and 5-GGAAACATGGGAAACATTCTGGACAGAGTATTGG-3 were used
to introduce the W401A, W401L, and W401F mutations, respectively, into the
RT gene in pBPol. Following site-directed mutagenesis, the ApaI-SalI fragment
in pBPol was subcloned into the ApaI-SalI sites of pSVC21 to generate the
proviral mutants HX-W401A, HX-W401L, and HX-W401F. The construct
pDRNL, containing the infectious NL4-3 molecular clone of HIV-1 (1), was used
to generate a clone containing the W401A mutation in the RT gene (NL-
W401A) by stitch PCR mutagenesis (6).
Transfections. 293T cells were seeded at 2 106 cells in 10-cm-diameter tissue
culture plates in DMEM-10 1 day prior to transfection. Proviral DNA constructs
(10 g/plate) were introduced into cells by using the calcium phosphate proce-
dure as previously described (38). An enhanced green fluorescent protein
(EGFP; Clontech)-expressing reporter plasmid (2 g) was cotransfected with the
HIV-1 plasmids to determine the transfection efficiency. At 8 h posttransfection,
cells were washed with phosphate-buffered saline without magnesium and cal-
cium [PBS()] and replenished with fresh DMEM-10. At 36 h posttransfection,
viruses and cells were harvested, and cell lysates were normalized according to
their transfection efficiency for Western blot analysis. For the examination of
viral protein profiles in viral lysates, infectivity assays, and cell-free RT assays, the
amounts of virus were normalized according to equivalent amounts of virion-
associated p24, as determined by Western blot analysis using p24 antibodies. For
transfections performed in the presence of indinavir, cells were pretreated with
0, 0.1, 1, or 10 M of drug, which was added to cells 1 h prior to transfection and
was maintained in the culture up to the time of harvesting of cells and virus.
Infectivity assays. The titer of HIV-1 produced from 293T cell transfections
was determined by end-point dilution in MT-2 cells. MT-2 cells (30,000 cells/ml)
were seeded into a 96-well tissue culture plate and inoculated with 10-fold serial
dilutions of virus in quintuplicate wells. Following day 6 postinfection, the virus-
specific cytopathic effect was scored in each well as either positive or negative in
order to calculate the 50% tissue culture infective dose using the Karber formula
(18). The amount of infectious virus was determined by using the TZM-bl
reporter cell line. TZM-bl cells were seeded in a 24-well tissue culture plate at 5
 104 cells per well 1 day prior to infection. Duplicate wells were infected with
a viral inoculum diluted in DMEM-10 containing DEAE-dextran (Amersham
Biosciences) at a final concentration of 40 g/ml. Cultures were incubated at
37°C in 5% CO2 for 48 h postinfection, fixed in 0.25% glutaraldehyde-0.8%
formaldehyde in PBS for 5 min at room temperature, and then stained with 400
g/ml of X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside), 4 mM
MgCl2, 4 mM potassium ferrocyanide, and 4 mM potassium ferricyanide in PBS
for 1 h at 37°C. Mock-infected cells were included and used to determine the
background. Following two washes with PBS, blue foci were counted by micros-
copy as previously described (8). The presence of equivalent amounts of virion-
associated p24 in culture supernatants for mutant and wild-type strains was
confirmed by a Western blot analysis of viral lysates purified through a 25%
(wt/vol) sucrose cushion prior to the infectivity assays. Since the numbers of viral
particles produced were similar for wild-type and mutant viruses, virus infectivity
in MT-2 and TZM-bl cells was expressed per ml of culture supernatant.
Viral protein analysis. For an analysis of viral proteins by Western blotting,
culture supernatants from transfected 293T cells were harvested at 36 h post-
transfection and clarified by low-speed centrifugation (2,000 rpm for 30 min;
Beckman GS-6R rotor), followed by concentration and partial purification of the
virus through a 25% (wt/vol) sucrose cushion (26,500 rpm, 1 h, 4°C) using an
SW41 rotor (Beckman). Viral pellets were solubilized in 80 l of 2 sodium
dodecyl sulfate (SDS) loading buffer and heated to 95°C for 3 min prior to the
separation of proteins in a 7.5% polyacrylamide gel containing sodium dodecyl
sulfate (SDS-polyacrylamide gel electrophoresis [SDS-PAGE]). For the analysis
of intracellular viral protein expression, transfected 293T cells were washed twice
with PBS(), collected in 5 ml of PBS(), and pelleted at 1,500 rpm for 10 min.
The cell pellet was lysed in 500 l of TNEN (10 mM Tris, pH 8.0, 50 mM NaCl,
1 mM EDTA, 1.0% Igepal CA-630 [Sigma-Aldrich, Castle Hill, NSW, Austra-
lia]) containing 1 g/ml each of aprotinin, leupeptin, and pepstatin. For exper-
iments performed with indinavir, the lysis buffer was also supplemented with 10
M drug. Lysates were centrifuged at 13,000  g at 4°C for 20 min, and the
supernatants were removed, added to an equal volume of 2 SDS loading buffer,
heated to 95°C for 3 min, and then subjected to SDS-PAGE. Following electro-
phoresis, proteins were transferred to polyvinylidene difluoride membranes (Mil-
lipore, North Ryde, NSW, Australia) by electroblotting and blocked for 1 h at
room temperature with 5% skim milk power in TBST (0.5% Tween 20, 137 mM
NaCl, 20 mM Tris), followed by incubation with primary and secondary antibod-
ies conjugated to horseradish peroxidase (Amersham Biosciences). Viral pro-
teins were detected by chemiluminescence per the manufacturer’s instructions
(Amersham Biosciences). The quantitation of viral protein bands from Western
blots was performed by densitometry using ScienceLab 99 Image Gauge, version
3.3, software (Fuji Photo Film Co. Ltd.) as previously described (28). The
statistical significance of differences between mutant and wild-type proteins was
determined using the Wilcoxon rank sum test (5, 42) for a minimum of three
independent assays, with data expressed as average relative intensities  stan-
dard deviations. The relative viral release efficiency (viral production) was cal-
culated as the amount of viral particle-associated Gag divided by the total (cell-
and viral particle-associated) amount of Gag as described previously (43).
Cell-free reverse transcriptase assay. Clarified viral lysates from transfections
were applied to an equal volume of 0.3% Igepal CA-630. The RT activity of viral
lysates (20 l) was assayed in the presence of 5 g/ml poly(rA)/oligo(dT) (Am-
ersham Biosciences), 10 Ci [-33P]dTTP (Perkin-Elmer, Boston, MA), 50 mM
Tris, pH 7.8, 7.5 mM KCl, 2 mM dithiothreitol, and 5 mM MgCl2 for 2 h at 37°C.
Samples were applied to DE 81 membranes and washed, and incorporated
counts were quantified by phosphorimager analysis as previously described (52).
Intracellular reverse transcriptase assay. Semiquantitative PCR was used to
detect reverse transcripts in lysates of MT-2 cells (4  105 cells/10 ml) infected
with wild-type and mutant viruses (500 ng of p24 quantified using the Vironostika
HIV-1 Antigen MicroElisa system [Biomerieux, Baulkham Hills, NSW, Austra-
lia]) which were harvested at 6 h postinfection. Cells were washed with PBS()
and prepared for PCR as previously described (49), except that cells were lysed
with 100 l of lysis buffer (1 HotStarTaq PCR buffer [QIAGEN, Clifton Hill,
Victoria, Australia], 0.5% Igepal CA-630, 0.5% Tween 20). Prior to infection,
viral stocks were filtered through 0.45-m filters and pretreated with 10 U of
RNase-free DNase I (Roche, Castle Hill, NSW, Australia) for 30 min at 37°C in
the presence of 10 mM MgCl2 to remove contaminating plasmid DNA. Ten-
microliter aliquots of undiluted cell lysates and either a 1/3, 1/10, or 1/30 dilution
of the cell lysates were assayed by PCR using HotStarTaq DNA polymerase
(QIAGEN) in a 50-l reaction mixture to detect early viral DNA synthesis
(R/U5) using the primer pair M667 (5-GGCTAACTAGGGAACCCACTG-3)
and AA55 (5-CTGCTAGAGATTTTCCACACTGAC-3) (66). The presence
of full-length or nearly full-length (long terminal repeat [LTR]/gag) viral DNA
transcripts was detected by PCR using the primer pair M667 and M661 (5-CC
TGCGTCGAGAGAGCTCCTCTGG-3) (66).
The amount of DNA in the lysates was standardized by PCR using the HLA-
DQ-specific primers GH26 (5-GTGCTGCAGGTGTAAACTTGTACCAG-
3) and GH27 (5-CACGGATCCGGTAGCAGCGGTAGAGTTG-3 (30). Ly-
sates from ACH2 cells, which contain a single copy of proviral DNA per cell (13),
were used for PCR quantitation as previously described (49).
Protein purification and size exclusion chromatography. Recombinant p66-
His and p66W401A-His were purified by Ni-nitrilotriacetic acid and DEAE-
Sepharose chromatography as previously described (31). The separation of RT
monomers and homodimers was performed by size exclusion chromatography
(SEC) using a Superdex 200 column (Amersham Biosciences) and a Pharmacia
fast-performance liquid chromatography system. The elution of RT subunits was
compared to the elution profiles of a mixture of eight molecular size standards
for gel filtration (range, 669 to 13.7 kDa) per the manufacturer’s instructions
(Amersham Biosciences). Samples (200 l) were resolved using a mobile-phase
(50 mM sodium phosphate, pH 7.8, 150 mM NaCl) flow rate of 0.25 ml/min. To
examine the proportions of monomers versus homodimers, purified wild-type
p66 or mutant p66W401A-His was diluted in the mobile phase to a final con-
centration of 3.8 M and resolved by SEC after 2 h of incubation on ice.
RESULTS
Mutations at RT codon 401 do not affect viral particle pro-
duction and Gag processing in virions. We have previously
demonstrated that the RT mutations W401A and W401L ne-
gate RT dimerization both in vitro and in the yeast two-hybrid
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system, while W401F has no effect on RT dimerization (51). To
determine if mutations that abrogate RT dimerization affect
viral production, we transfected 293T cells with infectious mo-
lecular clones of HIV-1 expressing the W401A (HX-W401A
and NL-W401A), W401L (HX-W401L), and W401F (HX-
W401F) RT mutations and compared the viral protein profiles
of the mutants to those of the corresponding isogenic wild-type
strains (HX-WT or NL-WT) (51) in both viral and cell lysates.
We examined the effect of the W401A mutation in the HXB-2
and NL4-3 genetic backgrounds to ensure that any observed
phenotypic effects were not strain dependent.
A Western blot analysis of both viral (Fig. 1) and cell lysates
(data not shown) from HIV-transfected cells probed with p24
antibodies demonstrated similar expression levels of viral Gag
for the mutant and isogenic wild-type strains. The relative viral
release efficiencies  standard errors for the mutant viruses
normalized to that of the wild type were 101  12 for HX-
W401F, 100  14 for HX-W401A, 98  13 for HX-W401L,
and 109 17 for NL-W401A. Statistical analysis demonstrated
that viral production was not significantly different for the
mutant W401 viruses compared to the isogenic wild-type
strains. These data demonstrate that mutations at W401 do not
affect viral particle production.
To determine whether the processing of Pr55gag to p24 was
altered in the mutant viruses, we performed a Western blot
analysis of viral lysates probed with p24 antibodies and deter-
mined the ratio of p24 to Pr55gag for HX-W401A, HX-W401L,
and HX-W401F compared to that for the wild-type virus (Fig.
1). Our analysis revealed no significant difference in the p24/
Pr55gag ratio for the mutants compared to that for the wild-
type virus (HX-WT, 1.10  0.05; HX-W401F, 1.05  0.11;
HX-W401A, 1.07  0.04; HX-W401L, 1.04  0.06). A similar
investigation of HIV-1 containing the W401A mutation in the
NL4-3 genetic backbone (NL-W401A) also revealed no signif-
icant difference in the processing pattern of Pr55gag to p24
compared to that for NL-WT (NL-WT, 1.05  0.04; NL-
W401A, 1.04  0.05) (Fig. 1). Taken together, these data
demonstrate that mutations near the RT dimer interface that
abrogate RT dimerization result in viruses that produce nor-
mal levels of viral particles with no detectable defects in Gag
processing.
The W401A/L RT mutations result in viral particles with
reduced infectivities. Since RT dimerization is critical for ac-
tivation of the RT enzyme (51, 53), we hypothesized that mu-
tations that cause defects in RT subunit interactions would
have detrimental effects on viral infectivity. In order to deter-
mine whether the viral particles with mutations at RT W401
were infectious, we subjected viruses obtained from the trans-
fection of 293T cells with the HIV-1 wild type and with mutant
clones to infectivity assays performed in MT-2 and TZM-bl
cells. For the detection of virus replication in MT-2 cells, the
virus must undergo multiple rounds of replication and spread
through the culture to produce detectable virus-specific cyto-
pathic effects by 6 days postinfection. Consequently, any dif-
ferences in viral infectivity will be amplified in this system
compared to assays in which the virus undergoes limited
rounds of infection, such as assays with the TZM-bl cell line.
The HIV-1 mutants HX-W401A, HX-W401L, and NL-W401A
demonstrated undetectable levels of infectious virus in MT-2
cells, while the titer of HX-W401F was fourfold less than that
of the wild type (Fig. 2A). We also assessed the infectivity of
the mutant viruses in the TZM-bl indicator cell line, which
contains a host cell chromosome-integrated LacZ gene under
the control of the HIV-1 LTR promoter (8). These cells can
measure a single round of infection, which is detected by trans-
activation of the LacZ reporter by newly synthesized Tat pro-
tein following integration of the viral DNA. Therefore, HIV-1
with defects in the early stage of replication up to and including
integration and the production of Tat would be expected to
display a reduced infectivity in this cell line. Under our assay
conditions (48 h), the cells would have been subjected to lim-
ited rounds of HIV infection. In this assay, HX-W401L was
noninfectious while HX-W401F was 2.5-fold less infectious
than HX-WT (Fig. 2B), similar to the data we observed with
the MT-2 infectivity assay. In contrast to the results of the
infectivity assay performed with MT-2 cells, the HX-W401A
and NL-W401A mutants demonstrated the presence of infec-
tious virus. Nevertheless, their infectivities were significantly
lower than that of the corresponding wild-type strains, with
100- and 50-fold decreases for HX-W401A and NL-W401A,
respectively (Fig. 2B). These data demonstrate a correlation
between the abrogation of RT dimerization in vitro and defects
in viral infectivity.
The W401A/L RT mutations result in viral particles with
defects in both virion particle-associated and intracellular RT
activity. We have shown that the HIV-1 mutants displayed
significant defects in infectivity (Fig. 2). We also know from
previous studies that viruses with mutations at W401 that ab-
rogate RT dimerization in vitro lack RT activity (51, 53).
Therefore, we examined the RT activity present in viral parti-
cles and the capacity of the RT in these particles to initiate and
complete intracellular reverse transcription. To measure RT
activity in virions, viral particles from 293T transfections (nor-
malized for p24) were subjected to a cell-free RT assay using
poly(rA)/oligo(dT) as a template primer. HX-W401A, HX-
W401L, and NL-W401A displayed 	1% of the RT activity of
the wild type in our assay, while the RT activity of the HX-
FIG. 1. Viral lysates probed with p24 antibodies. 293T cells were
cotransfected with an EGFP reporter plasmid and infectious molecular
clones of wild-type HIV-1 (HX-WT and NL-WT) or the W401 RT
mutants HX-W401F, HX-W401A, HX-W401L, and NL-W401A. At
36 h posttransfection, viruses and cells were harvested and normalized
to the transfection efficiency (according to EGFP expression) and
virion-associated p24 by Western blot analysis for the elucidation of
viral protein profiles in viral and cell lysates. Viruses were purified
from cell culture supernatants at 36 h posttransfection by centrifuga-
tion through a 25% (wt/vol) sucrose cushion. Viral pellets were solu-
bilized in 2 SDS loading buffer, and proteins were separated by
SDS-PAGE on a 7.5% polyacrylamide gel and subjected to Western
blot analysis using p24 antibodies. Viral bands were visualized by
chemiluminescence.
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W401F virus was 80% that of the wild type (Fig. 3A). These
data clearly show that viruses containing mutations known to
abrogate RT dimerization in vitro are defective in RT function.
To determine whether viral particles could initiate and com-
plete intracellular reverse transcription, we performed a semi-
quantitative PCR using primers that detect early transcripts
(minus-strand strong-stop DNA) and primers designed to de-
tect nearly complete viral DNA transcripts (66). MT-2 cells
were infected with viruses (normalized for p24) and at 6 h
postinfection were lysed for PCR analysis. A housekeeping
gene, HLA-DQ, was amplified from cell lysates and used to
normalize the cell lysates subjected to PCR for the detection of
HIV-1 reverse transcripts (data not shown).
HX401L demonstrated dramatic decreases in both early and
late transcripts (Fig. 3C). We also tested HIV-1 expressing the
L234A RT mutation (NL-L234A). Mutations at this residue
have been reported to confer a defect in Gag-Pol packaging,
and as a result, decreased packaging of RT in the virion (6, 65).
Hence, the NL-L234A mutant was expected to demonstrate a
FIG. 2. Infectivities of wild-type and W401 mutant viruses pro-
duced by transfection of 293T cells. Prior to infection, clarified 293T
cell supernatants containing wild-type or mutant virus were normalized
to equivalent amounts of virion-associated p24, as determined by
Western blot analysis. (A) Infectivities determined in a 6-day spread-
ing assay performed with MT-2 cells. Cells were infected in quintupli-
cate wells with 10-fold serial dilutions of virus. At 6 days postinfection,
the virus-specific cytopathic effect was scored and the 50% tissue
culture infective dose (TCID50) was calculated for each virus. Results
were obtained from three independent assays. (B) Infectivities deter-
mined with TZM-bl cells. Serially diluted viruses were used to infect
duplicate wells, and the numbers of blue-staining foci (infectious units)
were determined at 48 h postinfection as described in Materials and
Methods. Data were obtained from two independent assays. Error bars
indicate standard deviations.
FIG. 3. RT activities of wild-type and W401 mutant viruses. (A) Vi-
ruses from cell culture supernatants obtained from transfected 293T
cells expressing wild-type and W401 mutant viruses were normalized to
equivalent amounts of virion-associated p24, as determined by West-
ern blotting, lysed, and subjected to a cell-free RT assay using a
poly(rA)/oligo(dT) template/primer and an [-33P]dTTP substrate. In-
corporated counts were determined by phosphorimager analysis. Re-
sults were obtained from three independent assays. Error bars indicate
standard deviations. (B, C, and D) Semiquantitative PCRs for viral
DNA transcripts. The primer pair AA55 and MM67 was used to detect
early transcripts (ET), and MM61 and MM67 were used to detect late
transcripts (LT). (B) Dilution series of ACH2 cell lysate, which con-
tains one integrated copy of the HIV-1 provirus per cell, in addition to
PCR of uninfected MT-2 cells (mock). For panels C and D, superna-
tants from transfected 293T cells were clarified, treated with DNase I,
and used to infect MT2 cells using 500 ng of p24/4  105 cells. At 6
hours postinfection, the cells were collected, lysed, and then subjected
to PCR analysis. (C) PCRs were performed on undiluted (left) and
diluted (1/10) (right) MT-2 cell lysates infected with HX-W401L, NL-
L234A, and corresponding wild-type viruses. (D) MT-2 cell lysates
from infections with HX-W401A, NL-W401A, and corresponding
wild-type viruses were diluted 1/3, 1/10, and 1/30 (left to right). PCR
products were resolved in a 2% agarose gel and visualized by ethidium
bromide staining. The absence of contaminating plasmid DNA was
confirmed by performing PCR on the DNase I-treated cell culture
supernatant used for MT2 infection using both primer pairs (data not
shown).
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significant defect in intracellular RT function, as described for
the L234D mutant (65). In our system, NL-L234A was defec-
tive in the synthesis of both early and late transcripts compared
to the isogenic wild-type strain (Fig. 3B).
An analysis of the early and late transcripts synthesized by
the HX-W401A and NL-W401A mutants demonstrated de-
tectable decreases in both early and late transcripts compared
to HX-WT and NL-WT, respectively (Fig. 3D). The defects in
intracellular reverse transcription observed for the W401A
mutants were not as dramatic as those observed for the HX-
W401L mutant, particularly for early transcripts. These data
are consistent with the infectivity results obtained for these
mutants in the TZM-bl assay (Fig. 2B) and suggest that the
decrease in infectivity in these cells can be ascribed to a defect
in intracellular reverse transcription by the mutant RT en-
zymes.
The W401A/L RT mutations result in decreased levels of RT
in virions despite normal levels of Gag-Pol incorporation. Our
data suggest that mutations at the dimer interface that abro-
gate RT dimerization in vitro result in the production of viral
particles with markedly reduced infectivity as a result of defects
in RT function. One possibility for the RT defect is a reduced
incorporation of Gag-Pol in the virion, as described previously
(65). To exclude this possibility, we subjected viral lysates to
Western blot analysis with anti-RT (11G10) and anti-IN (8E5)
monoclonal antibodies (Fig. 4A). Compared to the wild type
and HX-W401F, both the HX-W401A and HX-W401L mu-
tants displayed reduced steady-state levels of the p66 and p51
RT subunits (ratio of viral p66wt to p66 mutant HX-W401F,
1.09  0.37 [P 
 0.125]; ratio of p66wt to HX-W401A, 0.59 
0.14 [P  0.048]; ratio of p66wt to HX-W401L, 0.39  0.16 [P
 0.048]; ratio of viral p51wt to p51 mutant HX-W401F, 1.06
 0.23 [P 
 0.125]; ratio of p51wt to HX-W401A, 0.57  0.16
[P  0.028]; ratio of p51wt to HX-W401L, 0.35  0.10 [P 
0.008]).
An analysis of the NL-W401A mutant also demonstrated a
trend toward lower levels of p66 and p51 in the virion than
those for NL-WT, which did not reach statistical significance
for p51 (ratio of viral p66wt to p66 mutant NL-W401A, 0.62 
0.10 [P  0.048]; ratio of viral p51wt to p51 mutant NL-
W401A, 0.78  0.11 [P  0.11]). Decreased levels of the two
RT subunits were also observed in viral lysates probed with
another RT monoclonal antibody (5B2) and with pooled sera
from HIV-infected individuals, indicating that the observed
results were not RT antibody specific (data not shown).
In contrast, no significant decrease in steady-state protein
levels of either Gag-Pol (the ratio of viral Gag-Pol to p24 for
HX-W401F normalized to the wild type was 1.04  0.18, that
for HX-W401A was 0.96  0.08, that for HX-W401L was 0.89
 0.19, and that for NL-W401A was 1.17  0.24) or IN (the
ratio of viral IN to p24 for HX-W401F normalized to the wild
type was 1.1  0.05, that for HX-W401A was 0.92  0.14, that
for HX-W401L was 1.01  0.19, and that for NL-W401A was
1.01  0.01) was detected in mutant virions compared to the
corresponding wild-type virus, suggesting that the decreased
levels of RT were unlikely to be a result of a defect in Gag-Pol
incorporation (Fig. 4A). These data are also consistent with
the lack of Gag processing defects observed in virions (Fig. 1)
and indicate that normal levels of PR and therefore of Gag-Pol
were incorporated into the mutant virus.
Intracellular processing of RT suggests a defect in p66 ho-
modimer formation. It has been postulated that the immediate
precursor to the HIV-1 RT heterodimer is the p66 homodimer
(59). Since both p66 subunits contain an RNase H domain, it
has been proposed that the RNase H domain of one of the
subunits must unravel in the p66 homodimer, exposing the PR
cleavage site between the Pol and RNase H domains and
leading to a 1:1 ratio of p66 to p51 in the virion (59). In vitro
studies using a minimal pol construct expressed in bacteria
support this hypothesis (45), but there are no data to shed light
on the mechanism of RT heterodimer formation in HIV-1-
infected cells. We have demonstrated that the W401A RT
mutation can abrogate RT heterodimerization (51) and p66
homodimerization (data not shown) in vitro. Hence, if the p66
homodimer is the immediate precursor to the RT heterodimer,
then the abrogation of p66 homodimerization should lead to a
decrease in processing to p51.
In order to gain insight into the nature of the immediate RT
heterodimer precursor, we examined RT expression in cell
lysates (Fig. 4B) of cells transfected with mutant and wild-type
viruses. Cell lysates from cells transfected with the virus ex-
pressing the W401A or W401L mutant displayed altered RT
processing profiles, where p51 was almost undetectable despite
FIG. 4. HIV protein profiles of viral and cell lysates from wild-type
and W401 mutant viruses. Viruses produced from 293T cells trans-
fected with infectious molecular clones of HIV-1 expressing wild-type
virus and the W401 RT mutants were purified through a 25% (wt/vol)
sucrose cushion, and viral pellets were solubilized in 2 SDS loading
buffer. 293T cells were washed, lysed, and clarified by centrifugation,
and equal volumes were added to 2 SDS loading buffer. Viral
(A) and cell (B) lysates were normalized according to virion-associated
p24 (by Western blotting) and transfection efficiency, separated by
SDS-PAGE on a 7.5% polyacrylamide gel, subjected to Western blot
analysis using RT (11G10) and IN (8E5) antibodies, and visualized by
chemiluminescence.
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the presence of p66, compared with those from wild type-
transfected cells and cells transfected with the dimerization-
competent HX-W401F mutant (ratios of intracellular p66 to
p51 for wild-type and mutant viruses were as follows: HX-WT,
1.97 0.31; HX-W401F, 1.66 0.42 [P 0.190]; HX-W401A,
3.44  0.94 [P  0.008]; HX-W401L, 5.40  2.17 [P  0.008];
NL-WT, 1.98  0.39; NL-W401A, 3.20  0.48 [P  0.05]). In
contrast, there was no detectable change in the intracellular
level of IN, suggesting that the defect was specific to RT pro-
cessing (Fig. 4B). The defect in processing to p51 can be
explained by the inability of p66 to form homodimers, which
may be a prerequisite for heterodimer formation. Taken to-
gether, these data suggest that mutations near the dimer in-
terface which negate RT dimerization in vitro lead to a defect
in the processing of p66 to the p51 subunit inside the infected
cell.
Mutant RT subunits are sensitive to proteolysis by HIV-1
protease. The decreased levels of RT in viral particles observed
with the HX-W401A/L and NL-W401A mutants is likely a
result of an increased susceptibility of the RT to proteolytic
degradation by proteases and not of decreased expression or
incorporation of Gag-Pol into the virion. To determine
whether the RT subunits were degraded by HIV-1 protease,
we transfected 293T cells with HX-WT and HX-W401L in the
absence and presence of indinavir, a specific inhibitor of HIV-1
protease (57), and probed viral and cell lysates with either
anti-p24 or the RT antibody 11G10. As expected, indinavir
treatment resulted in a dose-dependent inhibition of Pr55gag
processing to p24 for both wild-type (Fig. 5A) and mutant
viruses (Fig. 5C). As shown in Fig. 4A, viral lysates from
HX-WT obtained from transfections performed in the absence
of indinavir demonstrated almost a 1:1 ratio of p66:p51 in the
virion, and both subunits were also detectable in the cell lysates
(Fig. 5B). In contrast, markedly reduced steady-state protein
levels of p66 and p51 were observed in the HX-W401L viral
lysates in the absence of indinavir, while in cell lysates there
were decreased levels of p51 compared to HX-WT cell lysates
(Fig. 5B and D). The treatment of cells transfected with
HX-WT with increasing concentrations of indinavir led to a
dose-dependent decrease in the processing of Gag-Pol to p66
and p51 in both viral and cell lysates (Fig. 5B). Notably, viral
lysates from cells transfected with HX-W401L and treated with
0.1 M indinavir demonstrated levels of p66 and p51 ap-
proaching those observed with the wild-type virus cultured in
the absence of the drug. These data indicate that mutant RT is
more susceptible to proteolytic degradation than wild-type RT
and that HIV-1 PR is largely responsible for the reduced levels
of RT observed in HX-W401L virions.
FIG. 5. Western blot analysis of wild-type and W401L mutant viruses generated in the presence of the HIV-1 protease inhibitor indinavir. 293T
cells cultured in the presence of 0, 0.1, 1, or 10 M indinavir were transfected with HX-WT and HX-W401L constructs. Cell and viral lysates were
collected as described in Materials and Methods, normalized according to transfection efficiency, and subjected to SDS-PAGE and Western blot
analysis. Viral and cell lysates were probed with a p24 antibody (HX-WT [A] and HX-W401L [C]) or the RT antibody 11G10 (HX-WT [B] and
HX-W401L [D]). RT-related bands migrating at 62 and 45 kDa are denoted by solid arrowheads.
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Restored levels of virion RT in HX-W401L treated with
indinavir are not associated with restored RT activity. We
observed steady-state protein levels of p66 and p51 in viral
lysates from cells transfected with HX401L in the presence of
0.1 M indinavir which approached the levels observed with
the untreated wild-type virus (Fig. 5B and D). To determine
whether the RT in HX-W401L virions was functional, we sub-
jected virions to a cell-free RT assay. Virions obtained from
cells transfected with HX-WT in the absence of drug displayed
the highest RT activity, while decreased RT activity was ob-
served in virions from cells treated with increasing concentra-
tions of indinavir (data not shown). These data correlate with
a decrease in the processing of Gag-Pol to p66 and p51 in the
virion with increasing concentrations of indinavir (Fig. 5B). In
contrast, RT from cells transfected with HX-W401L was de-
void of RT activity when cultured in the absence and presence
of indinavir (data not shown), despite the increased levels of
p66 and p51 observed in the presence of 0.1 M indinavir (Fig.
5D). Our data demonstrate that the p66 and p51 RT subunits
in HX-W401L do not form a functional RT enzyme, despite
increased expression levels of these subunits in the presence of
0.1 M indinavir. These data suggest that the RT subunits fail
to form a stable heterodimer, which is consistent with our
previously described in vitro findings with recombinant RT
expressing this mutation (51).
The W401A mutation abrogates p66 homodimerization in
vitro. Our previous studies demonstrated that mutations that
abrogate RT dimerization (W401A/L) result in a recombinant
RT that fails to form a stable p66/p51 heterodimer. Further-
more, this dimerization-defective RT is devoid of RT activity,
as measured in an assay using an exogenous template/primer
(51). If the p66 homodimer is the immediate precursor of the
RT heterodimer, it is important to establish that mutations
that abrogate RT heterodimerization will also abrogate p66
homodimerization. Accordingly, we introduced the W401A
mutation into a construct expressing p66 with a C-terminal
histidine tag, expressed the mutant (p66W401A-His) in bacte-
ria, and purified the protein using nickel-nitrilotriacetic acid
and ion-exchange chromatography. Wild-type p66-His was also
expressed and purified in the same way. The proportion of
homodimer to monomer was resolved by SEC analysis on a
Superdex 200 column. Wild-type His-p66 at a concentration of
3.8 M was resolved as two peaks, representing p66 ho-
modimers (132 kDa) and p66 monomers (data not shown),
consistent with the known dissociation constant (KD) for p66
homodimerization (59). In contrast, p66W401A at the same
concentration was predominately monomeric (data not
shown). These data demonstrate that mutations that abrogate
RT heterodimerization also lead to defects in p66 homodimer-
ization.
DISCUSSION
We used mutations near the RT dimer interface which were
previously shown to inhibit RT heterodimerization in vitro to
probe the specific effects of abrogating RT dimerization on
HIV-1 replication. Our data show that the RT mutations
W401A and W401L result in the production of viruses with
markedly reduced infectivities due to decreased RT activity, as
observed both in cell-free RT assays and at the level of intra-
cellular reverse transcription. Furthermore, decreases in the
steady-state levels of the p66 and p51 RT subunits for the
W401L and W401A mutants were observed in virion lysates.
Importantly, the W401F mutation, shown not to significantly
inhibit RT dimerization in vitro, resulted in virions with rela-
tively small defects in viral infectivity, RT activity, and RT
maturation. These data indicate a strong correlation between
the abrogation of RT dimerization and defects in RT function
and maturation. Notably, the defect in viral infectivity was
remarkably specific to RT and did not appear to be a result of
the W401A/L mutations altering either Gag-Pol stability or the
incorporation of Gag-Pol into the virions.
The observed reductions in both RT activity and steady-state
protein levels of virion-associated p66 and p51 for the W401A
and W401L mutants can be ascribed to three possible mecha-
nisms: (i) an inability of the RT subunits to form stable and
functional dimers, thereby inhibiting RT function; (ii) an in-
creased susceptibility of the RT subunits to proteolytic degra-
dation by HIV-1 PR; and (iii) an increased susceptibility of a
Gag-Pol processing intermediate expressing RT to proteolytic
degradation by HIV-1 PR. Consistent with the first mechanism
is our observation that despite the restoration of p66 and p51
in HX-W401L virions to levels approaching those of the wild
type by indinavir treatment, the RT was nonfunctional in a
cell-free RT assay. The inability to form stable RT het-
erodimers and homodimers may also account for the increased
susceptibility of mutant RT to proteolytic degradation by
HIV-1 PR and possibly cellular proteases. We believe that the
third possibility is unlikely, as we did not observe a concomi-
tant degradation of HIV-1 IN along with the RT subunits in
either viral or cell lysates.
HIV PR-mediated processing of Gag and Gag-Pol is critical
for virus maturation (58). Gag processing occurs in a highly
ordered and sequential manner which is crucial for the pro-
duction of infectious virus (61). The processing of Gag-Pol is
also likely to occur in a highly regulated and sequential manner
for virion incorporation and proper maturation of the HIV-1
enzymes. The nature of the Gag-Pol cleavage intermediates in
HIV-1-infected cells has been determined by immunoblotting
using distinct antisera against HIV-1 proteins (33). The inter-
mediates include the initial autocatalytic cleavage reaction
products p120 and p113 (33). These products have also been
observed with a cell-free rabbit reticulocyte lysate system for
the study of PR activation in the context of full-length Gag-Pol
and are generated by autocatalytic cleavage between p2/NC
and transframe protein/p6pol (39, 40). Other processing inter-
mediates identified in HIV-1-infected cells include PR-RT-IN
(p107) and RT-IN (p97) (33). While the Gag-Pol processing
intermediates have been identified, we still do not know the
sequence of appearance of the processing products, which
would shed light on the Gag-Pol processing precursors that are
critical for RT maturation.
Two models have been proposed for the formation of the
p66/p51 RT during HIV-1 PR-mediated processing of
Pr160gag-pol (45). In the so-called sequential model, the RT
heterodimer is formed from a p66/p66 homodimer intermedi-
ate, while in the concerted model, the p66 subunits are formed
by processing from separate Gag-Pol molecules followed by
cleavage of some of the p66 to p51, which then associates with
the remaining p66. Structural studies (59) and experiments
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using a model Pol polyprotein (45) support the sequential
model, but no data exist to support this model in HIV-1-
infected cells. Our data demonstrate that the intracellular pro-
cessing of p66 to p51 in dimerization-defective mutants is not
efficient and that recombinant p66W401A does not form stable
p66/p66 homodimers in vitro. These data suggest that the re-
duced processing of p66 to p51 in cell lysates may be explained
by a failure of the mutant p66 to form homodimers. An alter-
native explanation for the reduced intracellular processing of
p66 to p51 is that the W401A/L mutations alter the conforma-
tion of p66 in such a way that the PR cleavage site between the
polymerase and the RNase H domain is not accessible. How-
ever, this possibility is not consistent with our observation of a
processing profile for the virion where the ratio of p66 to p51
was similar to that of the wild type. Furthermore, a circular
dichroism analysis of recombinant RT mutants expressing ei-
ther the W401A or W401L mutation demonstrated identical
profiles to that of wild-type RT, indicating that these mutations
do not lead to major changes in the RT secondary structure
(53). Therefore, our data support the sequential model for
p66/p51 heterodimer formation, as observed in cell lysates.
Paradoxically, while the processing of p66 to p51 was not
efficient in cells transfected with HX-W401A, HX-W401L, and
NL-W401A, the processing of p66 to p51 was not dramatically
inhibited in the viral particles, although the steady-state levels
of both subunits were less than those in the wild-type virus for
the HX-W401L and HX-W401A mutants. Since the effective
concentration of p66 subunits would be much higher in the
confines of the viral particle than in the cell, a possible expla-
nation for the difference in the RT processing pattern in cells
compared to virions is that mutant p66 is able to form loose or
transient homodimers in the virus, allowing cleavage of the
RNase H domain from one of the p66 monomers to p51.
Furthermore, the relative inability to form stable dimers may
explain the decreased stability of the RT subunits in response
to the high concentrations of HIV-1 PR in the virion, as mo-
nomeric or loose dimers of RT may be more susceptible to
proteolysis than stable RT dimers. Our hypothesis of weak/
transient dimer formation is consistent with the defects in RT
activity observed for the dimerization-defective mutants, since
it has been established that not only abrogation of RT dimer-
ization but also destabilization of the RT dimer leads to defects
in polymerase function (48). This has been demonstrated by
studies with the nonnucleoside reverse transcriptase inhibitors
1-{spiro[4-amino-2,2-dioxo-1,2-oxathiole-5,3-[2,5-bis-O-(tert-butyl-
dimethylsilyl)--D-ribofuranosyl]]}-3-ethylthymine (TSAOe3T)
and (4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydra-
zone (BBSH), which both inhibit the HIV-1 RT DNA poly-
merase activity of the heterodimers and p66 homodimers by
destabilization and not by abrogation of the RT subunit inter-
action (46, 47). The treatment of recombinant wild-type p66
and the W401A mutant RT with HIV-1 protease will help to
determine the relative susceptibilities of monomeric and
dimeric forms to proteolytic degradation in addition to
whether the cleavage site between Pol and RNase H is acces-
sible in the W401A mutant monomer.
Treatment with 0.1 M indinavir resulted in a partial resto-
ration of the steady-state levels of p66 and p51 in the HX-
W401L mutant viral particles, but RT activity remained unde-
tectable. We believe that the lack of RT activity in the cell-free
RT assay was due to the inability of the p66 and p51 RT
subunits to form stable heterodimers, as demonstrated in our
previous in vitro studies (51, 53). The lack of activity is unlikely
to be due to an inhibition of RT activity by the 62-kDa
polypeptide (migrating immediately underneath RT p66 in Fig.
5D) recognized by the RT antibody. A peptide of this size was
also observed for the wild-type virus treated with 0.1 M indi-
navir (Fig. 5B), which, in contrast to the W401L mutant, dis-
played significant levels of RT activity (50%) compared to
untreated wild-type virus (data not shown). An RT-specific
band at 45 kDa was also observed in HX-W401L viral lysates
harvested from 0.1 M indinavir-treated cells. In other exper-
iments, this band had similar intensities for both HX-WT and
HX-W401L treated with 0.1 M indinavir, indicating that it is
unlikely to be specific to the HX-W401L mutant. Furthermore,
the 45-kDa band is unlikely to interfere with heterodimer for-
mation, as a deletion of as little as 26 amino acids from p51
negates the interaction with p66 (25, 52).
The W401A and W401L mutant RTs displayed a 
99%
reduction in RNA-dependent DNA polymerase activity com-
pared to wild-type RT in the cell-free RT assay. A significant
reduction was also observed for minus-strand strong-stop and
late DNA synthesis for the W401L mutant and the L234A
control compared to wild-type HIV-1. In contrast, while the
virion-associated reverse transcriptase activity was dramatically
reduced compared to that of the wild type, we could still detect
significant levels of early DNA synthesis for NL-W401A and
HX-W401A compared to the wild type, with reverse transcrip-
tion defects becoming more apparent when we examined late
DNA transcripts. The greater RT defect by the W401L muta-
tion than by the W401A mutation correlates with the larger
decrease in viral infectivity of HX-W401L than of HX-W401A
in the infectivity assay performed with the TZM-bl cell line.
One possible explanation for detectable intracellular reverse
transcription, particularly for the W401A mutants, is that the
RT may behave differently on an artificial template/primer
from how it behaves when presented with the natural tRNALys
primer and genomic RNA template in the reverse transcription
complex. In vitro studies of recombinant RT with either the
W401L or W401A mutation also demonstrated a complete
inhibition of RNA-dependent DNA polymerase activity using
the same synthetic template/primer used for our RT assays
(51) and also using a template/primer based on the HIV-1
sequence (53). Therefore, one explanation for the difference in
RT activity in infected cells compared to that in vitro may be
due to the stabilizing presence of other viral or host cell factors
that modulate RT activity in the reverse transcription complex
(17, 19, 54, 55, 63). Another possibility for the difference in RT
activity of W401 mutants in cell-free assays compared to intra-
cellular reverse transcription can be ascribed to the dimeriza-
tion constant of the RT. The effective concentration of RT in
the confines of the reverse transcription complex is likely
higher than that in cell-free assays. Hence, the proportions of
dimers and monomers in the reverse transcription complex
would be higher, leading to a less dramatic defect than what we
observed in the cell-free assays.
Our study demonstrates a clear correlation between RT
dimerization-inhibiting mutations located near the RT dimer
interface and defects in RT maturation and function. The
defect in RT function was observed in the absence of detect-
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able effects on Gag-Pol stability or Gag-Pol incorporation into
the virion. Our studies suggest that the most likely precursor of
the mature RT heterodimer in HIV-1-infected cells is the p66
homodimer, although further studies are needed to prove this
assertion. Since the stability of the p66 homodimer is orders of
magnitude lower than that of the RT heterodimer, the former
represents a more attractive target for destabilization by small-
molecule inhibitors of HIV-1 RT.
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